Emergent BioSolutions Inc (EBS)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG, MD 20879

Emergent BioSolutions Inc. develops, manufactures, and commercializes immunobiotics such as vaccines and immune globulins that assist the body's immune system. The company's biodefense segment develops, manufactures, and commercializes drugs such as BioThrax, a vaccine for the prevention of anthrax, for use against biological agents. Other products in preclinical development include drugs for the treatment of patients after they are exposed to anthrax and botulinum toxin. Emergent's commercial segment develops products for use against infectious diseases. These include a single-dose typhoid vaccine in phase II clinical development; a hepatitis B vaccine in phase II clinical development, and a group B streptococcus vaccine for women of childbearing age for protection of the fetus and newborn babies, which is in phase I clinical trials. Emergent is also developing chlamydia and meningitis B vaccines. Emergent primarily works for the U.S. Defense and Health & Human Services departments. It has collaboration agreements with the British Health Protection Agency for the development of a human botulinum immune globulin candidate and with Sanofi Pasteur for the development of meningitis B vaccine candidate.

Data as of 2020-08-01
Market Cap5.832 Billion Shares Outstanding52.428 Million Avg 30-day Volume1.099 Million
P/E Ratio74.6 Dividend Yield EPS1.3
Price/Sales6.745 Price cash flow ratio36.2 Price free cash flow ratio50.3
Book Value20.5 Price to Tangible Book71.34 Alpha0.02
Short Interest Ratio4.7 % Short Interest to Float5.3 R-squared0.254736
BETA1.51975 52-week High/Low114.13 / 39.11 Stddev0.129553
View SEC Filings from EBS instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 5 2 (0.13%)
13F Filers holding this stock: 258 73 (4.78%)
Aggregate 13F shares on 03/31/2020: 44.688 Million 14.246 Million
Aggregate 13F shares on 12/31/2019: 44.988 Million 14.77 Million
Percent change: -0.67% -3.55%
Funds creating new positions: 50 18
Funds Adding to an existing position: 84 20
Funds closing out their position: 21 8
Funds reducing their position: 95 30
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding EBS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EBS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LABINGER BARRY PRESIDENT AND CEO

  • Officer
  • Director
0 2020-08-06 0

EL-HIBRI FUAD

  • Director
0 2020-07-27 13

ABDUN-NABI DANIEL

  • Director
0 2020-07-27 0

WHITE MARVIN L CEO AND PRESIDENT

  • Officer
  • Director
0 2020-07-27 0

NIEDERHUBER JOHN

  • Director
0 2020-07-27 0

HARSANYI ZSOLT

  • Director
0 2020-07-27 5

SULLIVAN LOUIS W

  • Director
9,420 2020-06-26 2

SMITH KAREN L.

  • Director
54,193 2020-06-11 1

ELSEY R DON

  • Director
104,456 2020-06-10 0

RICHARD RONALD

  • Director
4,269 2020-06-03 6

BAILEY SUE

  • Director
37,260 2020-06-03 4

HAUER JEROME M

  • Director
10,188 2020-05-26 3

ZOON KATHRYN C

  • Director
13,489 2020-05-26 7

MULLIGAN SEAMUS

  • Director
1,152,788 2020-05-26 0

JOULWAN GEORGE A

  • Director
32,771 2020-05-21 2

KRAMER ROBERT PRESIDENT AND CEO

  • Officer
  • Director
142,203 2020-05-08 2

STREI KATHERINE EVP, CHIEF HR OFFICER

  • Officer
28,009 2020-05-08 2

LINDAHL RICHARD S EVP, CHIEF FINANCIAL OFFICER

  • Officer
31,806 2020-05-08 2

HAVEY ADAM EVP, BUSINESS OPERATIONS

  • Officer
34,256 2020-04-17 3

KIRK SEAN EVP, MANUFACTURING & TECH OPS

  • Officer
12,571 2020-04-06 3

SARAN ATUL EVP, CORP DEV, GC & SECRETARY

  • Officer
40,799 2020-02-25 1

EMERGENT BIOSOLUTIONS INC.

  • SEAN KIRK, EVP, MANUFACTURING
13,604 2019-05-23 0

INTERVAC, L.L.C.

  • 10% Owner
0 2016-08-01 0

CHATFIELD STEVEN EVP, BIOSCIENCES

  • Officer
28,000 2013-03-14 0

ALLBAUGH JOE M

  • Director
523,713 2011-07-01 0

KEESE KYLE EVP, BIOSCIENCES DIVISION

  • Officer
18,759 2011-03-15 0

LOCKHART STEPHEN SVP PRODUCT DEVELOPMENT

  • Officer
6,980 2010-11-11 0

BIOPHARM, L.L.C.

  • 10% Owner
No longer subject to file 2010-05-27 0

ESPOSITO DENISE CLO

  • Officer
0 2009-03-10 0

BIOLOGIKA, L.L.C.

  • MEMBER 13(D) GROUP OWNING >10%
1,399,764 2008-06-04 0

MICHIGAN BIOLOGIC PRODUCTS, INC.

  • MEMBER 13(D) GROUP OWNING >10%
1,328,018 2008-01-14 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments